Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
| Autor: | Kelley, Robin Kate *, *, Rimassa, Lorenza *, Cheng, Ann-Lii, Kaseb, Ahmed, Qin, Shukui, Zhu, Andrew X, Chan, Stephen L, Melkadze, Tamar, Sukeepaisarnjaroen, Wattana, Breder, Valery, Verset, Gontran, Gane, Edward, Borbath, Ivan, Rangel, Jose David Gomez, Ryoo, Baek-Yeol, Makharadze, Tamta, Merle, Philippe, Benzaghou, Fawzi, Banerjee, Kamalika, Hazra, Saswati, Fawcett, Jonathan, Yau, Thomas |
|---|---|
| Zdroj: | In The Lancet Oncology August 2022 23(8):995-1008 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|